When individuals with HIV are released from prison, they have difficulty obtaining care and are often unable to adhere to their HIV medications and maintain viral suppression. Relapse to opioid use often occurs quickly after release from prison or jail and interferes with HIV treatment adherence. Medications that are effective in reducing relapse to opioid use are rarely started prior to release.
According to a new study, an FDA-approved medication for opioid addiction - extended-release naltrexone - has now been shown to also help maintain or improve HIV viral suppression among HIV-positive individuals released from prison and jail who are on HIV treatment and have a history of opioid use disorder.
Published: Thursday, April 26, 2018
